HIV/AIDS-Test and Treat
HIV/AIDS-Test and Treat
Editors
Atul Kakar DNB FRCP
Vice Chairman Department of Internal Medicine Member, GRIPMER Governing Body Sir Ganga Ram Hospital
New Delhi, India
Samiran Nundy MA MChir FRCS FRCP
Emeritus Consultant Department of Surgical Gastroenterology and Liver Transplantation
Editor-in-Chief Current Medicine Research and Practice Adviser, GRIPMER
New Delhi, India
Foreword
BB Rewari

Headquarters
Jaypee Brothers Medical Publishers (P) Ltd.
4838/24, Ansari Road, Daryaganj
New Delhi 110 002, India
Phone: +91-11-43574357
Fax: +91-11-43574314
E-mail: jaypee@jaypeebrothers.com
Overseas Offices
JP Medical Ltd.
83, Victoria Street, London
SW1H 0HW (UK)
Phone: +44-20 3170 8910
Fax: +44(0)20 3008 6180
E-mail: info@jpmedpub.com
Jaypee Brothers Medical Publishers (P) Ltd.
17/1-B, Babar Road, Block-B, Shyamoli
Mohammadpur, Dhaka-1207
Bangladesh
Mobile: +08801912003485
E-mail: jaypeedhaka@gmail.com
Jaypee-Highlights Medical Publishers Inc.
City of Knowledge, Bld. 235, Clayton
Panama City, Panama
Phone: +1 507-301-0496
Fax: +1 507-301-0499
E-mail: cservice@jphmedical.com
Jaypee Brothers Medical Publishers (P) Ltd.
Bhotahity, Kathmandu, Nepal
Phone: +977-9741283608
E-mail: kathmandu@jaypeebrothers.com
Website: www.jaypeebrothers.com
Website: www.jaypeedigital.com
© 2018, Jaypee Brothers Medical Publishers
The views and opinions expressed in this book are solely those of the original contributor(s)/author(s) and do not necessarily represent those of editor(s) of the book.
All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission in writing of the publishers.
All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.
Medical knowledge and practice change constantly. This book is designed to provide accurate, authoritative information about the subject matter in question. However, readers are advised to check the most current information available on procedures included and check information from the manufacturer of each product to be administered, to verify the recommended dose, formula, method and duration of administration, adverse effects and contraindications. It is the responsibility of the practitioner to take all appropriate safety precautions. Neither the publisher nor the author(s)/editor(s) assume any liability for any injury and/or damage to persons or property arising from or related to use of material in this book.
This book is sold on the understanding that the publisher is not engaged in providing professional medical services. If such advice or services are required, the services of a competent medical professional should be sought.
Every effort has been made where necessary to contact holders of copyright to obtain permission to reproduce copyright material. If any have been inadvertently overlooked, the publisher will be pleased to make the necessary arrangements at the first opportunity. The CD/DVD-ROM (if any) provided in the sealed envelope with this book is complimentary and free of cost. Not meant for sale .
Inquiries for bulk sales may be solicited at: jaypee@jaypeebrothers.com
HIV/AIDS-Test and Treat
First Edition : 2018
9789352703876
Printed at:
- Shrihari Anil Anikhindi
- Divya Arora
- Sairam B
- Bobby Bhalotra
- Vinant Bhargava
- Kunal Chawla
- Sanghamitra Datta
- Veronique Dinand
- Shilpa Garg
- Lovy Gaur
- Parul Goel
- Atul Gogia
- Shweta Mittal Gupta
- Isra Halim
- Atul Kakar
- Dinesh Kaul
- Jyoti Kotwal
- Ashish Kumar
- Kishan Majithiya
- Chandra Mansukhani
- Manishi Nautiyal
- Rashmi Nigam
- Jaswinder Kaur Oberoi
- Reena Raveendran
- Darshit Shah
- Ajay Sharma
- Akanksha Tandon
- Roopal Verma
- Chand Wattal
HIV epidemic in India has witnessed an immense contribution from wide range of people ranging from skilled or partially-skilled dedicated field workers to the highly qualified technical professionals, clinicians and researchers. The epidemic has graduated over the period of last 30 years and has cruised through various phases that coincide with the interventions made at individual levels, community levels and organizational levels. Astonishing and tireless efforts have been invested so far in designing and implementing the health program interventions to deal with the epidemic through public health approach at national, regional and local levels by the government of India through state governments and various communities, organizations and individuals. The successful achievements of the public health prevention, control and treatment programs could never have been possible without the evidence generation by the researchers and technical inputs provided by the experienced clinicians that manage the illnesses and sufferings of the patients in clinics.
Evidence base of HIV medicine has evolved extremely rapidly in recent past globally, so much so that by the time the knowledge is accumulated in form of a chapter of a book, new evidence will await at the corner. A wealth of information is available on-line, in form of various guidelines and updates. Though crucial, often the on-line information baffles the end users, especially busy clinicians, to choose and apply the knowledge while managing the patients in the clinics. The clinicians deal with diversified situations in practice viz establishing the diagnosis of HIV, when to initiate the anti-retro viral treatment, what anti-retro viral drug combinations will be the most suitable for the patient, how to identify and manage the toxicities of the anti-retro viral drugs, prophylaxis and treatment for the opportunistic infections, management of coinfections, comorbidities and malignancies, prevention of transmission of HIV to others especially from mother to child and also after occupational exposure to infected materials, and palliative care or end of life care for those who need it. The widely available online information often seems in sufficient to aid a treating physician when managing an actual case in a clinic or hospital.
This book is a prudent attempt to match the requirements of those clinicians and practitioners who desire to know a snapshot of vast recent knowledge out there that can benefit them in managing HIV in their clinics or hospitals. Authors of each chapter of this book have displayed dazzling skills by spelling out often complicated and difficult concepts around HIV diagnosis and management in a way that will assist clinicians, practitioners, students, program managers, and others interested, while approaching the HIV infection. I hope the enthusiasm expressed by the team of authors is translated in practice. My best wishes are with the team.
I congratulate Dr Atul Kakar for this great book and the work he is doing for care and support to those infected and affected by HIV/AIDS.
BB Rewari MD FRCP FICP
AG Regional Advisor HIV and Scientist—HIV/STI/Hepatitis
World Health Organization Regional office for South-East Asia
Associate Professor
Department of Global Health
University of Washington
Seattle, Washington, USA
Preface
The Human Immunodeficiency Virus (HIV) is the etiological agent of the acquired immunodeficiency syndrome (AIDS). It belongs to the family of human retroviruses (retroviridae) and subfamily of Lentivirus and mainly reproduces in CD4+ T lymphocytes and monocytes/macrophages causing severe immunological impairment. With the advent of anti-retro viral therapy (ART) the mortality and morbidity with patients living with HIV/AIDS has decreased.
The HIV epidemic has seen three major clinical themes over the past few years. According to many authors, the first decade started in 1981, when we use to treat only the opportunistic infection, manage the crisis and HIV management was limited to palliation provided by primary healthcarers. However, from1991 onwards, with the availability of anti-retro viral therapy, the focus has become more on specialized medicine given by HIV specialists who have a better understanding of viral pathogenesis. From 2001 to 2011, we were in a chronic disease era for HIV management. This also included managing the effects of HIV on the kidney, liver, central nervous system, heart and bone.
Malignancies in people living with HIV/AIDS have also become another area of concern in the last few years. Even nearly two decades into the modern anti-retro viral (ARV) era, the risk of death continues to drop for people living with HIV. Many things resulted in a change in the lives of patients with HIV/AIDS.
These are enumerated below:
- In the field of diagnosis, early analysis can be done. The 4th generation HIV test has added the P24 antigen which can permit the diagnosis even before antibodies against HIV are formed (seroconversion). The advantages of earlier diagnosis include decreasing the risk of transmission, immune protection and possible cure.
- After so many years of the epidemic being amongst us we can talk of a cure in HIV. The word ‘Cure’ in the HIV setting has two categories. If the virus is totally eliminated it is called a sterilizing cure and if the virus continues to be present in the body but the viraemia does not require anti-retro viral therapy (ART) it is called a functional cure.
- From the therapic point of view, all the major guidelines now suggest treatment should be given to all HIV patients irrespective of their CD4 cell counts. This test and treat approach improves the quality of life of HIV patients and also decreases the incidence of new infection. According to 2015 statistics, 0.05% of the world's population is currently newly infected with HIV every year. With an aim of getting all patients under the umbrella of anti-retro viral therapy, this incidence should come down leading to a lower burden on physicians.
- The other positive thing which has happened is doctor education. The care of HIV is now simpler and more and more physicians are getting involved as they are becoming familiar with the drug regimen and also with the complications of therapy. Because of this HIV management has become more like chronic care provided by primary care physicians.
- We now have new and safer drugs to combat infection. Efavirenz 600 mg is an important front line drug included in many guidelines including those of the WHO. However, the drug was previously associated with many side effects including suicidal ideas. Recent trials have demonstrated that 400 mg of the drug is non-inferior to 600 mg over the period of 96 weeks to achieve virological clearance and with less side effects.
- Another important drug which is used in management is Tenofovir disoproxil fumarate. Presently Tenofovir is also a front line drug in patients with HIV AIDS. Its use has been associated with renal toxicity, Fanconi syndrome like features and also osteopenia/osteoporosis. Tenofovir alpha phenamine is a novel type of pro drug which should be available in the Indian market soon. By switching over to the prodrug, the side effect profile becomes favorable with less bone and renal toxicity.
- Another important drug which has minimal side effects is Dolutegravir. This drug is a second generation integrase inhibitor. It can be given to a naïve patient as the first line therapy and also to patients who are failing on many anti-retro viral third line/salvage therapies. It has got a good safety profile. The major side effects of the drug include mild nausea, headache and sleep disorder. However, the drug is new to India and we need to see the side effect profile and where it should be placed in the management algorithm.
- Once a month therapy for HIV is an excellent innovation available in the form of an injection. It contains two drugs, Cabotegravir and Rilpivirine, which need to be administered in both buttocks. Studies have demonstrated that the viral load is well controlled upto 30 days with a single dose. This is one step forward toward controlling HIV infection by replacing the daily pill burden and also in patients with problems of compliance.
- The last word has to be about the HIV vaccine which is the need of the hour. Following many unsuccessful attempts moderate efficacy has been demonstrated with RV144 and AIDS VAX B/E. However, we are still a long way from a commercially available vaccine.
Atul Kakar
Samiran Nundy
Acknowledgments
No book gets completed without help from its authors and we would especially like to thank our contributors for the efforts they made and the quality of their contributions to this book. We are also grateful for the encouragement and support given to us by Dr DS Rana, Chairman, Board of Management as well as Dr PS Gupta, Dr SP Byotra and Dr Kusum Verma, Dean GRIPMER (The Ganga Ram Institute for Postgraduate Medical Education and Research) who are always there behind us during all our educational activities.
Last but not least, we would like to thank Mr Parmanand Tiwari, Junior Executive, in our hospital who has helped us right from the beginning to the completion of this important publication.